Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 25, 2025
Subject: Announcement of positive headline results from a Phase 2 clinical trial of amycretin in patients with type 2 diabetes.
Key Financial Metrics
This filing is a clinical trial update and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Results
The filing reports significant clinical efficacy for amycretin, a unimolecular agonist of GLP-1 and amylin receptors, compared to placebo in a study of 448 participants with type 2 diabetes inadequately controlled on metformin (with or without SGLT2 inhibitors).
- HbA1c Reduction (Subcutaneous): Dose-dependent reductions of up to -1.8% from a baseline of 7.8%. Up to 89.1% of patients achieved HbA1c levels below 7%, and 76.2% achieved levels ≤6.5%.
- HbA1c Reduction (Oral): Dose-dependent improvements of up to -1.5% from a baseline of 8.0%.
- Weight Loss (Subcutaneous): Statistically significant weight loss of up to -14.5% from a baseline of 99.2 kg, compared to -2.6% for placebo.
- Weight Loss (Oral): Statistically significant weight loss of up to -10.1% from a baseline of 101.1 kg, compared to -2.5% for placebo.
- Safety Profile: Amycretin appeared safe and well-tolerated. The most common adverse events were gastrointestinal, with the vast majority being mild to moderate in severity.
Guidance, Outlook, and Management Commentary
Management Commentary: Martin Holst Lange, Chief Scientific Officer, stated the data validates the potential "best-in-class profile" of amycretin due to its complementary biology of GLP-1 and amylin.
Outlook and Next Steps:
- Novo Nordisk plans to initiate a Phase 3 development program with amycretin for adults with type 2 diabetes in 2026.
- The company intends to expand the program across multiple indications.
Risks and Contingencies: The filing notes that adverse events were consistent with other incretin and amylin-based therapies, primarily gastrointestinal in nature. No specific financial risks or contingencies were disclosed in this text.
Key Facts for Investor Verification
- Verify the timeline and design of the planned Phase 3 trials scheduled for initiation in 2026.
- Monitor the long-term safety data regarding gastrointestinal adverse events as the drug moves to larger Phase 3 cohorts.
- Assess the competitive landscape for GLP-1/amylin dual agonists in the type 2 diabetes and obesity markets.
- Confirm the specific dosing regimens selected for Phase 3 based on the dose-response data presented (subcutaneous 0.4-40 mg weekly; oral 6-50 mg daily).